RedHill Biopharma (RDHL) Total Non-Current Liabilities (2022 - 2024)

RedHill Biopharma (RDHL) has disclosed Total Non-Current Liabilities for 3 consecutive years, with $503000.0 as the latest value for Q4 2024.

  • Quarterly Total Non-Current Liabilities fell 49.45% to $503000.0 in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $503000.0 through Dec 2024, down 49.45% year-over-year, with the annual reading at $503000.0 for FY2024, 49.45% down from the prior year.
  • Total Non-Current Liabilities for Q4 2024 was $503000.0 at RedHill Biopharma, down from $995000.0 in the prior quarter.
  • The five-year high for Total Non-Current Liabilities was $9.8 million in Q4 2022, with the low at $503000.0 in Q4 2024.
  • Average Total Non-Current Liabilities over 3 years is $3.8 million, with a median of $995000.0 recorded in 2023.
  • The sharpest move saw Total Non-Current Liabilities crashed 89.86% in 2023, then tumbled 49.45% in 2024.
  • Over 3 years, Total Non-Current Liabilities stood at $9.8 million in 2022, then plummeted by 89.86% to $995000.0 in 2023, then plummeted by 49.45% to $503000.0 in 2024.
  • According to Business Quant data, Total Non-Current Liabilities over the past three periods came in at $503000.0, $995000.0, and $9.8 million for Q4 2024, Q4 2023, and Q4 2022 respectively.